Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for NTRK fusion-positive non-small-cell lung cancer, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Fusions are missed when only DNA panels are run.
Neurological side effects from TRK inhibition are class-wide.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Data specific to lung cancer come from small cohorts within basket trials.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
Repotrectinib produced responses in 79 percent of ROS1 inhibitor-naive patients (median progression-free survival 35.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
ORR 75% by independent review in the first 55 pooled patients across 17 tumour types.
A milestone in how this cancer is treated.